Armata Pharmaceuticals, Inc.
ARMP
$1.42
$0.06815.04%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.17M | 5.47M | 3.72M | 4.70M | 4.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.17M | 5.47M | 3.72M | 4.70M | 4.53M |
| Cost of Revenue | 50.54M | 49.64M | 49.46M | 49.24M | 50.83M |
| Gross Profit | -45.37M | -44.17M | -45.74M | -44.54M | -46.30M |
| SG&A Expenses | 13.18M | 13.04M | 13.38M | 12.29M | 11.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.61M | 46.94M | 45.78M | 44.47M | 45.42M |
| Operating Income | -42.44M | -41.48M | -42.06M | -39.77M | -40.89M |
| Income Before Tax | -18.92M | -41.36M | -67.04M | -79.58M | -69.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.92 | -41.36 | -67.04 | -79.58 | -69.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.92M | -41.36M | -67.04M | -79.58M | -69.05M |
| EBIT | -42.44M | -41.48M | -42.06M | -39.77M | -40.89M |
| EBITDA | -41.11M | -40.24M | -40.91M | -38.71M | -39.92M |
| EPS Basic | -0.52 | -1.15 | -1.86 | -2.20 | -1.91 |
| Normalized Basic EPS | -0.91 | -0.86 | -0.85 | -0.76 | -0.75 |
| EPS Diluted | -1.62 | -1.64 | -2.35 | -2.28 | -1.98 |
| Normalized Diluted EPS | -0.72 | -0.77 | -0.75 | -0.70 | -0.69 |
| Average Basic Shares Outstanding | 144.64M | 144.56M | 144.47M | 144.38M | 144.30M |
| Average Diluted Shares Outstanding | 189.63M | 166.65M | 166.56M | 164.86M | 164.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |